Direct oral anticoagulants and cancer-associated VTE: good for all, or just some?

Blood. 2020 Aug 6;136(6):669-673. doi: 10.1182/blood.2019004177.

Abstract

Venous thromboembolism (VTE) is associated with significant mortality and morbidity in patients with cancer. Therefore, tailoring anticoagulation is of utmost importance to decrease the risk of recurrent VTE while minimizing the risk of bleeding. Direct oral anticoagulants have been recently compared with low-molecular-weight heparin for the management of acute cancer-associated thrombosis. Although direct oral anticoagulants are a welcome addition, clinicians need to incorporate clinical characteristics, drug-drug interactions, and patient preference in decision making.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Administration, Oral
  • Aged
  • Antithrombins / pharmacology
  • Antithrombins / therapeutic use
  • Drug Interactions
  • Factor Xa Inhibitors / adverse effects
  • Factor Xa Inhibitors / pharmacology
  • Factor Xa Inhibitors / therapeutic use*
  • Female
  • Hemorrhage / chemically induced
  • Heparin, Low-Molecular-Weight / adverse effects
  • Heparin, Low-Molecular-Weight / pharmacology
  • Heparin, Low-Molecular-Weight / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Neoplasms / blood*
  • Neoplasms / complications
  • Pilot Projects
  • Randomized Controlled Trials as Topic
  • Thrombophilia / drug therapy*
  • Thrombophilia / etiology
  • Venous Thromboembolism / drug therapy*
  • Venous Thromboembolism / etiology
  • Venous Thromboembolism / prevention & control

Substances

  • Antithrombins
  • Factor Xa Inhibitors
  • Heparin, Low-Molecular-Weight